A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
The Latest on: Retinitis pigmentosa
via Google News
The Latest on: Retinitis pigmentosa
- BRITISH SCIENTISTS’ AMAZING ‘STEM CELL CURE’ FOR BLINDNESS on April 12, 2019 at 5:00 pm
There is no cure for retinitis pigmentosa, an inherited condition that slowly constricts vision, but a British firm has reported early success with a revolutionary procedure that helps to repair a ... […]
- AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials on April 8, 2019 at 4:08 am
The company also completed enrollment in the expansion group, which includes pediatric patients, of its product candidate (rAAV2tYF-GRK1-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) ... […]
- Retinitis Pigmentosa (RP) Market - Thoughtful Insights, Facts, Historical Data, and Statistical Support 2017-2025 on March 26, 2019 at 9:27 pm
Retinitis Pigmentosa (RP), an inherited retinal condition causing retinal degeneration and visual field loss, is a rare disease. Its initial symptoms are reduced night vision and loss of peripheral ... […]
- WHAT’S UP DOC? No effective treatment for retinitis pigmentosa on March 12, 2019 at 4:24 am
Q: Retinitis pigmentosa runs in my fiancé’s family. Should he get tested before we have kids? A: Light enters the eye through the cornea and is focused onto the retina (which acts like the "movie ... […]
- Carl Arredondo. longtime WWL-TV meteorologist, stepping down due to retinitis pigmentosa on February 21, 2019 at 4:46 pm
Carl Arrendondo, WWL-TV's chief meteorologist and a fixture on the Louisiana weather forecast scene for 28 years, will retire March 1 due to vision problems, the station announced this afternoon. ... […]
- Retinitis Pigmentosa (RP) Market – Insights on Trending Need 2025 on February 20, 2019 at 2:57 am
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and ... […]
- What causes retinitis pigmentosa? on February 7, 2019 at 4:00 pm
More than 60 different genes can cause the different forms of retinis pigmentosa. Parents can pass the problem genes on to their children in three different ways: Autosomal recessive retinitis ... […]
- What Is Retinitis Pigmentosa? on February 7, 2019 at 4:00 pm
Retinitis pigmentosa (RP) is a term for a group of eye diseases that can lead to loss of sight. What they have in common is a coloring your doctor sees when he looks at your retina -- a bundle of ... […]
- Untapped Medical Needs to Drive Retinitis Pigmentosa Market towards Growth – Finds TMR Research on February 4, 2019 at 10:21 pm
Retinitis pigmentosa is a medical condition inherited, which causes retinal degeneration. Since there are no treatments available for curing retinitis pigmentosa, they are much awaited and a great ... […]
- Carolyn Marshall Covington: Triangle woman serves as role model for Black History Month on February 1, 2019 at 3:47 pm
5 things to know: She is a veteran of the beauty industry. She was diagnosed with Retinitis Pigmentosa, an incurable condition that eventually causes blindness. She was inspired to create Insightful ... […]
via Bing News